VERTEX PHARMACEUTICALS INC reported first-quarter adjusted profit of $4.47 per share, beating LSEG estimates of $4.31 per share. Revenue rose 8% to $2.99 billion, driven by a 687% sales surge for the new cystic fibrosis therapy Alyftrek. The results highlight Vertex's successful shift toward new treatments as its legacy blockbuster Trikafta missed analyst sales expectations.

Alyftrek Momentum Offsets Trikafta Miss